Gene Solutions Indonesia Collaborates with POGI Banten for Hybrid Event on NIPT

On August 4th 2024, Gene Solutions Indonesia, in collaboration with the Indonesian Gynecological and Obstetric Society (POGI) Banten Branch, hosted a hybrid event through Alomedika titled “Beyond NIPT – Integrating Maternal Carrier Screening with NIPT” to highlight the advancements in Non-Invasive Prenatal Screening and its role in identifying both prenatal and maternal conditions beyond genetic chromosome detection.

The event featured notable speakers, including Dr. Didi Danukusumo, an Obstetrics and Gynecology Specialist, initiated the discussion on integrating maternal carrier screening with NIPT. He particularly focused on the importance of thalassemia carrier screening in prenatal care and underlined the need to consider the types of genetic conditions that test can cover, their performance based on international guidelines and their relevance to the local population.

Following this, Dr. Sandhy Prayudhana, another expert in Obstetrics and Gynecology Specialist, provided in-depth review of factors leading to false positive and false negative NIPT results. He highlighted trisure NIPT’s high accuracy, exceptional negative predictive value (NPV), and positive predictive value (PPV), affirming its reliability and relevance for prenatal care in Indonesia.

The hybrid format of the event included a panel discussion, Q&A session that allowed participants to engage in the advancements in NIPT and its role in addressing critical health issues like Thalassemia in Indonesia. Attendees gained insights into the capabilities of NIPT with cutting-edge #NGS technology and proprietary algorithms based on the rich genetic data of Asian pregnant women, and Gene Solutions’ prenatal product offerings, exploring potential solutions for enhancing clinical practice.

POGI MFM now recommends all pregnant women to be offered NIPT test due to their high accuracy and safety. This collaborative effort between Gene Solutions Indonesia and POGI Banten showcased the potential of NIPT to improve health outcomes for expectant mothers and their babies in Indonesia.

 About Gene Solutions Indonesia:

Established in 2022, PT Gene Solutions Indonesia has been diligently advancing genetic testing and providing essential support to healthcare practitioners. We recognize the significance of Next-Generation Sequencing (NGS) in prenatal care and molecular diagnostics. Through our valued partnership with KALGen INNOLAB, we strive to make Non-Invasive Prenatal Testing (NIPT) and oncology diagnostics accessible to the Indonesian population.

Follow Gene Solutions Indonesia on Instagram to get the latest updates: https://www.instagram.com/genesolutions.id/am.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More